<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584295</url>
  </required_header>
  <id_info>
    <org_study_id>ECCO2R2018</org_study_id>
    <nct_id>NCT03584295</nct_id>
  </id_info>
  <brief_title>Early Extubation by ECCO2R Compared to IMV in Patients With Severe Acute Exacerbation of COPD</brief_title>
  <acronym>X-COPD</acronym>
  <official_title>A Multicenter, Randomized-controlled Trial of Extracorporeal CO2 Removal (ECCO2R) to Facilitate Early Extubation Compared to Invasive Mechanical Ventilation in Patients With Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Witten/Herdecke</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate if veno-venous (vv)-extracorporeal carbon dioxide Removal
      (ECCO2R) is capable of reducing mortality and/or severe disability at day 60 after
      randomisation in patients with severe acute exacerbation of chronic obstructive pulmonary
      disease (COPD) requiring invasive mechanical ventilation (IMV). Extubation will be
      facilitated by vv-ECCO2R and compared to IMV alone in a randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study hypothesizes an advantage for veno-venous extracorporeal carbon dioxide
      removal (vv-ECCO2R) in severe acute exacerbation of COPD requiring invasive mechanical
      ventilation (IMV) to facilitate early extubation in terms of reducing mortality or severe
      disability. The study hypothesizes that avoiding IMV could reduce mortality and substantially
      improve quality of life, especially in regard to avoidance of tracheostomy and long-term home
      IMV. Improvement in mobility due to sooner recovery has a further major impact on patients'
      QoL.

      After randomization patients with acute exacerbation of severe COPD, requiring invasive
      mechanical ventilation will be treated either with conventional care or vv-ECCO2R to
      facilitate early extubation. Vv-ECCO2R is used in a standard configuration with either double
      lumen cannula (20-22Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow
      rate between 1-2 L/min.

      Conventional care in the control arm includes invasive mechanical ventilation and the attempt
      to extubate the patient as early as possible and to switch to non-invasive ventilation (NIV).
      If extubation fails, tracheostomy can be performed according to the discretion of the
      treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or severe disability</measure>
    <time_frame>day 60</time_frame>
    <description>Death or severe disability at day 60 after randomization. Severe disability is defined as confinement to bed and/or inability to wash or dress alone and/or need for long-term invasive mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year mortality or severe disability</measure>
    <time_frame>1 year</time_frame>
    <description>Change in mortality/severe disability rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia during ICU treatment</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in Pneumonia rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on IMV/ Time on extracorporeal life support (=duration of support)</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in days on IMV/Time on extracorporeal life support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at 60 and 360 days (EQ-5D)</measure>
    <time_frame>60 days and 360 days</time_frame>
    <description>Change in Quality of life index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility, measured with ActiGraph</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in activity per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment costs</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in absolute treatment costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for tracheostomy</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in rate of tracheostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintubation rate</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Change in Reintubation rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>Conventional care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extracorporeal carbon dioxide Removal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide Removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (20-22Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-2 L/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal carbon dioxide Removal</intervention_name>
    <description>Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation</description>
    <arm_group_label>Extracorporeal carbon dioxide Removal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Care</intervention_name>
    <description>Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.</description>
    <arm_group_label>Conventional care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute exacerbation of COPD requiring invasive mechanical ventilation

          -  Known history of COPD

          -  Acute and potentially reversible cause of acute respiratory failure as determined by
             the treating physician

        Exclusion Criteria:

          -  Intubated and mechanically ventilated for more than 7 days up to randomization

          -  COPD exacerbations requiring invasive mechanical ventilation for more than 7 days
             within the last 12 months

          -  ratio of arterial oxygen partial pressure to fractional inspired oxygen &lt;120 mmHg

          -  Age &lt;18 years or &gt;75 years

          -  Contraindication for Heparin anticoagulation (aPTT 1.5-2x of normal range)

          -  Severe chronic liver disease (Child Pugh&gt;11)

          -  End-stage medical condition other than COPD

          -  Acute pulmonary embolism requiring lysis therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Karagiannidis, M.D., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Witten/Herdecke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Karagiannidis, M.D., Prof.</last_name>
    <phone>+49/221-8907-18809</phone>
    <email>christian.karagiannidis@uni-wh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Hage-HÃ¼lsmann</last_name>
    <email>Anne.hage-huelsmann@uni-wh.de</email>
  </overall_contact_backup>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

